Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial | Zendy

Remo H.M. Furtado | Zendy; Itamar Raz | Zendy; Erica L. Goodrich | Zendy; Sabina A. Murphy | Zendy; Deepak L. Bhatt | Zendy; Lawrence A. Leiter | Zendy; Darren K. McGuire | Zendy; John Wilding | Zendy; Philip E. Aylward | Zendy; Anthony J. Dalby | Zendy; Mikael Dellborg | Zendy; Doina Dimulescu | Zendy; José Carlos Nicolau | Zendy; A. J. M. Oude Ophuis | Zendy; Avivit Cahn | Zendy; Ofri Mosenzon | Zendy; Ingrid GauseNilsson | Zendy; Anna Maria Langkilde | Zendy; Marc S. Sabatine | Zendy; Stephen D. Wiviott | Zendy

Open Access

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

Author(s) -

Remo H.M. Furtado,

Itamar Raz,

Erica L. Goodrich,

Sabina A. Murphy,

Deepak L. Bhatt,

Lawrence A. Leiter,

Darren K. McGuire,

John Wilding,

Philip E. Aylward,

Anthony J. Dalby,

Mikael Dellborg,

Doina Dimulescu,

José Carlos Nicolau,

A. J. M. Oude Ophuis,

Avivit Cahn,

Ofri Mosenzon,

Ingrid GauseNilsson,

Anna Maria Langkilde,

Marc S. Sabatine,

Stephen D. Wiviott

Publication year - 2022

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.121.058103

Subject(s) - medicine , dapagliflozin , timi , kidney disease , blood pressure , hazard ratio , myocardial infarction , cardiology , heart failure , type 2 diabetes , diabetes mellitus , renal function , placebo , thrombolysis , endocrinology , confidence interval , pathology , alternative medicine

Dapagliflozin improved heart failure and kidney outcomes in patients with type 2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the DECLARE-TIMI 58 trial (Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58). Here, the aim was to analyze the efficacy and safety of dapagliflozin stratified according to baseline systolic blood pressure (SBP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research